As Eli Lilly (LLY) Shares Rose, Saturna Capital Corp Cut by $7.70 Million Its Stake

July 13, 2018 - By Theresa Judd

Eli Lilly and Company (NYSE:LLY) LogoInvestors sentiment decreased to 0.78 in Q1 2018. Its down 0.32, from 1.1 in 2017Q4. It dived, as 76 investors sold LLY shares while 427 reduced holdings. 82 funds opened positions while 308 raised stakes. 810.94 million shares or 1.95% less from 827.08 million shares in 2017Q4 were reported. Intact Management owns 2,800 shares or 0.01% of their US portfolio. D E Shaw & Co invested 0.27% of its portfolio in Eli Lilly and Company (NYSE:LLY). Smithfield holds 1,620 shares. Renaissance Techs Limited Liability Corporation reported 3.76 million shares stake. Stock Yards National Bank & Trust accumulated 0.34% or 39,029 shares. Shell Asset Mngmt accumulated 293,096 shares. Cambridge Investment Research Advsr holds 0.13% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 153,952 shares. Sectoral Asset Mngmt holds 1.54% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 182,100 shares. Cwm Ltd Liability stated it has 0% in Eli Lilly and Company (NYSE:LLY). Jolley Asset Lc reported 2,210 shares. Cambridge holds 0.06% or 11,324 shares. Avalon Ltd Liability Com accumulated 281,469 shares. Vantage Inv Prns has 0.91% invested in Eli Lilly and Company (NYSE:LLY). Putnam Ltd Liability Co has invested 0.37% in Eli Lilly and Company (NYSE:LLY). State Of Alaska Department Of Revenue holds 0.35% in Eli Lilly and Company (NYSE:LLY) or 216,836 shares.

Since February 1, 2018, it had 1 insider purchase, and 21 sales for $123.15 million activity. The insider Conterno Enrique A sold 25,000 shares worth $2.13 million. Shaw Christi sold $691,775 worth of stock. Simmons Jeffrey N sold $708,620 worth of stock. The insider Skovronsky Daniel bought $862,200. $237,600 worth of stock was sold by Smiley Joshua L on Friday, March 16. The insider Zakrowski Donald A sold 900 shares worth $72,981.

Saturna Capital Corp decreased its stake in Eli Lilly (LLY) by 8.03% based on its latest 2018Q1 regulatory filing with the SEC. Saturna Capital Corp sold 100,000 shares as the company’s stock rose 3.23% while stock markets declined. The institutional investor held 1.15M shares of the major pharmaceuticals company at the end of 2018Q1, valued at $88.59M, down from 1.25 million at the end of the previous reported quarter. Saturna Capital Corp who had been investing in Eli Lilly for a number of months, seems to be less bullish one the $91.31 billion market cap company. The stock increased 0.62% or $0.55 during the last trading session, reaching $89.46. About 1.49 million shares traded. Eli Lilly and Company (NYSE:LLY) has risen 5.65% since July 13, 2017 and is uptrending. It has underperformed by 6.92% the S&P500.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on July, 24 before the open. They expect $1.34 EPS, up 20.72 % or $0.23 from last year’s $1.11 per share. LLY’s profit will be $1.37 billion for 16.69 P/E if the $1.34 EPS becomes a reality. After $1.34 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More important recent Eli Lilly and Company (NYSE:LLY) news were published by: which released: “Better Buy: Eli Lilly and Company vs. AbbVie” on July 09, 2018, also published article titled: “Better Buy: Acadia Pharmaceuticals vs. Eli Lilly”, published: “Your Daily Pharma Scoop: IPO Review – Aptinyx Surges, Kezar Progresses, Neon Slumps” on July 11, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) was released by: and their article: “Where Did Major Pharma Short Sellers Go?” with publication date: July 12, 2018.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 11 analysts covering Eli Lilly & Co (NYSE:LLY), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Eli Lilly & Co had 18 analyst reports since January 16, 2018 according to SRatingsIntel. Credit Suisse maintained it with “Underperform” rating and $84 target in Thursday, June 21 report. On Monday, January 22 the stock rating was downgraded by Credit Suisse to “Underperform”. The rating was maintained by J.P. Morgan on Monday, June 11 with “Buy”. The rating was maintained by BMO Capital Markets with “Market Perform” on Wednesday, April 25. Cantor Fitzgerald initiated Eli Lilly and Company (NYSE:LLY) rating on Thursday, June 7. Cantor Fitzgerald has “Buy” rating and $10000 target. The stock has “Hold” rating by Leerink Swann on Thursday, February 1. The rating was maintained by Jefferies with “Buy” on Friday, April 13. The stock of Eli Lilly and Company (NYSE:LLY) earned “Hold” rating by Goldman Sachs on Tuesday, January 16. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, April 13. Bank of America maintained Eli Lilly and Company (NYSE:LLY) on Thursday, February 1 with “Neutral” rating.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.